News

Sanctura XR, the once-daily formulation of Sanctura, is a quaternary ammonium compound and belongs to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax

Mr Engle succeeds Jack Castello, the company’s former president and CEO, who announced his retirement plans earlier this year. Mr Castello will remain with the company as non-executive

Tezampanel is an AMPA/kainate (AK) receptor antagonist that offers a non-opioid, non-vascular and non-serotonergic approach to the management of pain. The company says that it represents a potentially

Upon close of the transaction Avanir received an upfront payment of $42 million, plus $1.9 million in working capital adjustments. Under the terms of the agreement, Avanir could

Leo Pharma is GTC Biotherapeutics’s partner for ATryn in Europe, Canada and the Middle East. The drug is GTC Biotherapeutics’s recombinant form of human antithrombin, which has both

The patent has also been granted in New Zealand, South Africa and India and is pending in other countries. The novel compounds covered by Via’s latest patent exhibit

Last year the Indian government denied a patent for cancer treatment Gleevec on the grounds that the drug was insufficiently innovative. Under Indian law, minor improvements to major

GSK also reported the start of the first North American pre-pandemic vaccine trials in the company’s global pre-pandemic influenza program. The company has received a second task order

The Nigerian government is suing the pharmaceutical giant for roughly $8.5 billion in damages. It is also pressing criminal charges on the grounds of unethical testing of Trovan,